VV116 Noninferior to Nirmatrelvir-Ritonavir for COVID-19

FRIDAY, Jan. 6, 2023 -- VV116 is noninferior to nirmatrelvir-ritonavir with respect to time to sustained clinical recovery for adults with mild-to-moderate COVID-19 at risk for progression, according to a study published online Dec. 28 in the New...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news